Travere Therapeutic
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-02-07
- Employees
- 380
- Market Cap
- -
- Website
- http://www.travere.com
- Introduction
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
- Conditions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02998710
- Locations
- 🇬🇧
Travere Investigational Site, Salford, Manchester, United Kingdom
🇺🇸Travere Investigational Site - Virtual Site, Culver City, California, United States
🇺🇸Travere Investigational Site (Enrolling 1 to <5 Year-olds Only), Philadelphia, Pennsylvania, United States
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
- Conditions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02638220
- Locations
- 🇺🇸
Travere Investigational Site, Milwaukee, Wisconsin, United States
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT01613118
- Locations
- 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
🇺🇸University of Washington, Seattle, Washington, United States